Literature DB >> 10414181

Surgical treatment of cholangiocellular carcinoma.

U Hanack1, T Lorf, L Binder, F Braun, J W Oestmann, B Sattler, B Ringe.   

Abstract

Cholangiocarcinoma is a primary liver tumor arising from the small bile ducts within the liver. According to its different location, clinical features, frequency of metastases, treatment modalities and prognosis, intrahepatic cholangiocarcinoma should well be differentiated from proximal bile duct carcinoma. To date, there is no therapeutic measure with curative potential apart from surgical treatment. Partial hepatectomy is the treatment of choice. It is of overriding importance to achieve microscopically tumor-free margins. However, only few patients treated in an early stage have a prolonged recurrence-free survival or a chance for cure. Liver transplantation is not an alternative therapeutic option for unresectable cholangiocarcinoma, due to early tumor recurrence in almost all recipients. Liver transplantation has a place in preventing cholangiocarcinoma in primary sclerosing cholangitis, although the timing of replacement is still a matter of debate. Results of surgery need further improvement by adjuvant or neoadjuvant treatment protocols.

Entities:  

Mesh:

Year:  1999        PMID: 10414181     DOI: 10.1024/1023-9332.5.3.111

Source DB:  PubMed          Journal:  Swiss Surg        ISSN: 1023-9332


  2 in total

1.  The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium.

Authors:  A C Okaro; A R Deery; R R Hutchins; B R Davidson
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

2.  Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy.

Authors:  Thomas J Vogl; Wolfram Schwarz; Katrin Eichler; Kathrin Hochmuth; Renate Hammerstingl; Ursula Jacob; Albert Scheller; Stephan Zangos; Matthias Heller
Journal:  J Cancer Res Clin Oncol       Date:  2006-07-21       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.